Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Adolescent
Adult
Aged
Amikacin
/ blood
Anti-Bacterial Agents
/ pharmacokinetics
Drug Elimination Routes
/ physiology
Female
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Kidney
/ physiology
Kidney Function Tests
Male
Mexico
Microbial Sensitivity Tests
Middle Aged
Prospective Studies
Young Adult
PK/PD modeling
amikacin
augmented renal clearance
population pharmacokinetics
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
29
10
2019
accepted:
03
02
2020
pubmed:
12
2
2020
medline:
23
3
2021
entrez:
12
2
2020
Statut:
epublish
Résumé
The aim of this work was to evaluate the pharmacokinetics of amikacin in Mexican patients with different renal functions receiving once-daily dosing regimens and the influence of clinical and demographical covariates that may influence the optimization of this antibiotic. A prospective study was performed in a total of 63 patients with at least one determination of amikacin plasma concentration. Population pharmacokinetic (PK) parameters were estimated by nonlinear mixed-effects modeling; validations were performed for dosing recommendation purposes based on PK/pharmacodynamic simulations. The concentration-versus-time data were best described by a one-compartment open model with proportional interindividual variability associated with amikacin clearance (CL) and volume of distribution (
Identifiants
pubmed: 32041715
pii: AAC.02178-19
doi: 10.1128/AAC.02178-19
pmc: PMC7179627
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Amikacin
84319SGC3C
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Nefrologia. 2010;30(2):143-6
pubmed: 20393616
CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17;2:e38
pubmed: 23887688
Pharmacotherapy. 2019 Mar;39(3):346-354
pubmed: 30723936
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12
pubmed: 7310648
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Clin Drug Investig. 1998;15(5):435-44
pubmed: 18370499
Int J Clin Pharmacol Ther. 2011 Jun;49(6):371-81
pubmed: 21612744
Intensive Care Med. 2014 Jul;40(7):998-1005
pubmed: 24687298
J Infect Dis. 1987 Jan;155(1):93-9
pubmed: 3540140
Nefrologia. 2010;30(3):324-30
pubmed: 20414326
Fundam Clin Pharmacol. 1995;9(1):57-61
pubmed: 7768489
Clin Pharmacokinet. 2017 Feb;56(2):127-138
pubmed: 27324191
Drugs R D. 2017 Mar;17(1):177-187
pubmed: 28063020
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31481443
Chest. 2012 May;141(5):1327-1336
pubmed: 22553267
Biomed Res Int. 2013;2013:202818
pubmed: 23484093
Crit Care Med. 1997 May;25(5):806-11
pubmed: 9187600
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Scand J Infect Dis Suppl. 1990;74:129-32
pubmed: 2129064
J Basic Clin Pharm. 2016 Jun;7(3):65-9
pubmed: 27330257
Clin Pharmacokinet. 2010;49(1):1-16
pubmed: 20000886
Comput Methods Programs Biomed. 1999 Jan;58(1):51-64
pubmed: 10195646
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2:e50
pubmed: 23836189
J Clin Pharmacol. 1991 Feb;31(2):158-63
pubmed: 2010561
Ann Pharmacother. 2012 Mar;46(3):317-28
pubmed: 22395245
Eur J Clin Pharmacol. 1983;24(5):643-7
pubmed: 6873144
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
Anaesth Crit Care Pain Med. 2019 Aug;38(4):335-336
pubmed: 30857924
Antimicrob Agents Chemother. 1990 Apr;34(4):614-21
pubmed: 2111658
J Antimicrob Chemother. 1991 Nov;28(5):753-64
pubmed: 1778878
Nephron. 1976;16(1):31-41
pubmed: 1244564
Antimicrob Agents Chemother. 1999 Mar;43(3):623-9
pubmed: 10049277
Ther Drug Monit. 2010 Dec;32(6):749-56
pubmed: 20962708
DICP. 1989 Apr;23(4):316-23
pubmed: 2658376